Accuracy of the COMPASS-CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The COMPASS-CAT tool shows diagnostic value in predicting venous thromboembolism (VTE) for cancer patients. Further research is recommended for broader cancer types and larger patient cohorts.
Area Of Science
- Oncology
- Hematology
- Diagnostic Accuracy
Background
- Venous thromboembolism (VTE) is a significant complication in cancer patients.
- Accurate prediction tools are crucial for timely intervention and management.
Purpose Of The Study
- To systematically review and assess the diagnostic accuracy of the COMPASS-CAT tool for VTE prediction in cancer patients.
Main Methods
- A comprehensive literature search was conducted across multiple databases up to April 2023.
- Study quality was assessed using the QUADAS-2 tool.
- Meta-analysis and meta-regression were performed using Stata MP 17.0.
Main Results
- Thirteen studies with 8,665 patients were included.
- The COMPASS-CAT score demonstrated a pooled sensitivity of 0.76 and specificity of 0.67 (AUC=0.77).
- Higher accuracy was observed in international outpatient settings (sensitivity=0.94, AUC=0.86) compared to domestic inpatient settings (sensitivity=0.65, AUC=0.78).
Conclusions
- The COMPASS-CAT score possesses diagnostic value for VTE in cancer patients.
- The tool effectively identifies patients at risk, though heterogeneity exists.
- Future research should focus on diverse cancer types and large-scale, multi-center prospective studies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
